DiaMedica Therapeutics Q2 EPS $(0.16) Beats $(0.18) Estimate
Portfolio Pulse from vinayak@benzinga.com
DiaMedica Therapeutics reported Q2 losses of $(0.16) per share, beating the analyst consensus estimate of $(0.18) by 11.11%. However, this is a 23.08% decrease over losses of $(0.13) per share from the same period last year.
August 14, 2023 | 8:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
DiaMedica Therapeutics reported better than expected Q2 losses, but the losses increased compared to the same period last year.
While DiaMedica Therapeutics beat the analyst consensus estimate for Q2 losses, the fact that the losses increased compared to the same period last year could have a neutral impact on the stock. Investors may be encouraged by the better than expected results, but also concerned about the increased losses.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100